---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-22-001472"
form_type: "8-K"
ticker: "IMUX"
cik: "0001280776"
company_name: "IMMUNIC, INC."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T08:13:22.302491+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Immunic Q3 net loss $21.2M; goodwill impairment ~$33M; cash $129M; IMU-935 psoriasis trial misses

## Summary
- Net loss $21.2M ($0.69/share) vs $19.3M ($0.76) in Q3 2021; R&D $16.5M, G&A $3.6M.
- Cash $72.8M at Sept 30; plus $56.4M net from Oct private placement => runway into Q4 2024.
- Expects goodwill impairment of ~$33M in Q4 2022 due to stock decline after IMU-935 psoriasis data.
- IMU-935 psoriasis phase 1b: interim data showed no separation from placebo; high placebo rate; update Q1 2023.
- IMU-856 phase 1 Parts A/B positive; Part C in celiac disease ongoing, data 2023; patent allowance received.

## SEC filing metadata
- accession: 0001193805-22-001472
- form_type: 8-K
- ticker: IMUX
- cik: 0001280776
- company_name: IMMUNIC, INC.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1280776/000119380522001472/0001193805-22-001472-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1280776/000119380522001472/e617987_8k-immunic.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-22-001472
- JSON: https://secwatch.observer/filing/0001193805-22-001472.json
- Plain text: https://secwatch.observer/filing/0001193805-22-001472.txt

## Key facts
- Earnings Releases
  IMMUNIC, INC. reported financial results for the third quarter ended September 30, 2022.
  - Period: the third quarter ended September 30, 2022
  - Result: reported results
  source text: On November 3, 2022, Immunic, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022 and providing a corporate update
  evidence_url: https://www.sec.gov/Archives/edgar/data/1280776/000119380522001472/0001193805-22-001472-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.